ARA 290 – 16MG per vial

Clinical Test Expectation – ARA 290 – Human Subjects : Anti-inflammatory and immunomodulatory functions to down-regulate inflammation to alleviate neuropathic pain
Strength – 16MG per vial

Introduction
ARA 290 is an erythropoietin-derived polypeptide that possesses analgesic and tissue protective effect in many diseases such as diabetes and cancer. The analgesic effect of this peptide is mediated by its anti-inflammatory and immunomodulatory functions, or more specifically, by targeting the innate repair receptor (IRR) to down-regulate inflammation to alleviate neuropathic pain. However, whether other mechanisms or pathways are involved in ARA 290-mediated analgesic effect remains elusive. In this study, we are particularly interested in whether ARA 290 could directly target peripheral nociceptors by blocking or influencing receptors in pain sensation. Using calcium imaging, cell culture and behavioral tests, we demonstrated that ARA 290 was able to specifically inhibit TRPV1 channel activity, and relieve the mechanical hypersensitivity induced by capsaicin. Our study suggested that this peptide could potentially function as a novel antagonist for TRPV1 channel. This finding would not only contribute to the development of new pain treatment using this peptide, but also help to improve our understanding of the integration between the immune system and the peripheral nervous system.

Dosing Details – Please visit this link for Dosing instructions : https://researchpeptides.co.za/dosage-instructions/